NCT00110838

Brief Summary

The objective of the SOFA trial is to investigate whether supplemental intake of n-3 polyunsaturated fatty acids (n-3 PUFA) from fish oil can reduce the recurrence of life-threatening ventricular arrhythmias in patients with an implantable cardioverter defibrillator (ICD).

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
546

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Oct 2001

Typical duration for phase_3

Geographic Reach
8 countries

27 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2001

Completed
3.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2005

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 13, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 16, 2005

Completed
Last Updated

July 21, 2006

Status Verified

May 1, 2005

First QC Date

May 13, 2005

Last Update Submit

July 20, 2006

Conditions

Keywords

fish oiln-3 fatty acidsn-3 PUFAomega-3 fatty acidsarrhythmiaICDhumanPatients with an implantable cardioverter defibrillator

Outcome Measures

Primary Outcomes (1)

  • Occurrence of appropriate ICD intervention (shock or antitachycardia pacing) for spontaneous ventricular tachyarrhythmias, or all-cause mortality

Secondary Outcomes (5)

  • All cause mortality (separately from ventricular tachyarrhythmia)

  • Cardiac mortality

  • Myocardial infarction

  • All arrhythmic events as documented by the ICD Core laboratory

  • Change in the prescription of antiarrhythmic drugs

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ICD is capable of recording ECG strips for at least 10 of its (attempted) therapeutic interventions
  • years or older
  • written informed consent

You may not qualify if:

  • Primary prophylactic indication
  • ICD implantation as a 'bridge' to heart transplantation
  • Refractory supraventricular arrhythmias with rapid ventricular rates despite antiarrhythmic therapy
  • a projected lifespan of less than 1 year
  • participation in another trial (during or within 30 days before SOFA)
  • use of any supplemental n-3 fatty acid during the last 3 months
  • intake of more than 8g of n-3 fatty acids from fish per month as judged by a fish frequency questionnaire
  • pregnant women and women of childbearing potential who do not use adequate contraception
  • patients known to have a history of recent drug or alcohol abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (27)

Wilhelminenspital

Vienna, A-1160, Austria

Location

Universitair Ziekenhuis Gent

Ghent, B-9000, Belgium

Location

Interni Kardiologicka Klinika

Brno, 63900, Czechia

Location

Institute of Clinical and Experimental Medicine

Prague, 14021, Czechia

Location

Kerckhoff-Klinik GmbH

Bad Nauheim, D-61231, Germany

Location

Herz- und Diabeteszentrum Nordrhein-Westfalen

Bad Oeynhausen, D-32545, Germany

Location

Klinikum Benjamin Franklin Berlin

Berlin, 12200, Germany

Location

Charité - Universitätsmedizin Berlin

Berlin, 13353, Germany

Location

Klinikum der Friedrich-Schiller-Universitat

Jena, D-07747, Germany

Location

Stiftsklinik Augustinum

Munich, 81375, Germany

Location

Universitatsklinikum Muenster

Münster, 48149, Germany

Location

Academic Medical Centre Amsterdam

Amsterdam, 1105 AZ, Netherlands

Location

Catharina Ziekenhuis

Eindhoven, 5623 EJ, Netherlands

Location

St. Antoniusziekenhuis

Nieuwegein, 3435 CM, Netherlands

Location

University Medical Center Rotterdam Erasmus

Rotterdam, 3015 GD, Netherlands

Location

University Medical Centre Utrecht

Utrecht, 3584 CX, Netherlands

Location

Wageningen Centre for Food Sciences

Wageningen, 6703 HD, Netherlands

Location

Isala Klinieken (Locatie Wezenlanden)

Zwolle, 8011 JW, Netherlands

Location

Medical University of Gdansk

Gdansk, 80-211, Poland

Location

I Klinika Kardiologii

Katowice, 40-635, Poland

Location

Pomeranian Academy of Medicine

Szczecin, 70-111, Poland

Location

Instytut Kardiologii

Warsaw, 02-637, Poland

Location

Grochowski Hospital

Warsaw, 04-073, Poland

Location

Centre Hospitalier Universitaire Voudois

Lausanne, 1011, Switzerland

Location

Queen Elizabeth Hospital

Birmingham, B15 2TH, United Kingdom

Location

St George Hospital Medical School

London, SW17 ORE, United Kingdom

Location

Southampton General Hospital

Southampton, SO16 6YD, United Kingdom

Location

Related Publications (2)

  • Brouwer IA, Zock PL, Wever EF, Hauer RN, Camm AJ, Bocker D, Otto-Terlouw P, Katan MB, Schouten EG. Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. Eur J Clin Nutr. 2003 Oct;57(10):1323-30. doi: 10.1038/sj.ejcn.1601695.

    PMID: 14506496BACKGROUND
  • Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H, Schouten EG; SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006 Jun 14;295(22):2613-9. doi: 10.1001/jama.295.22.2613.

MeSH Terms

Conditions

Arrhythmias, Cardiac

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Evert G Schouten, MD, PhD

    Wageningen Centre for Food Sciences

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 13, 2005

First Posted

May 16, 2005

Study Start

October 1, 2001

Study Completion

January 1, 2005

Last Updated

July 21, 2006

Record last verified: 2005-05

Locations